Sanofi completes the acquisition of Vigil Neuroscience, Inc.Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. ('Vigil”). This acquisition ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025.